Table 1. Baseline characteristics stratified by gender of the patients enrolled in the IDI Research Cohort.
| Characteristics | Total N = 559 | Females N = 386 (69%) | Males N = 173 (31%) | P value |
|---|---|---|---|---|
| Age in years, median (IQR) | 38 (33–44) | 34 (29–40) | 38 (33–42) | 0.00 |
| WHO clinical stage 3 and 4 | 496 (89%) | 339 (87.8%) | 158 (91.3) | 0.22 |
| BMI (Kg/m 2 ), median (IQR) | 20 (17–22) | 20.3 (18.2–22.7) | 19.4 (17.5–21.0) | 0.00 |
| Hb g/dL, median (IQR) | 11.5 (10.3–12.9) | 11.2 (10.0–12.5) | 12.6 (11.0–14.1) | 0.00 |
| CD4 count cell/μL, median (IQR) | 98 (21–163) | 100 (29–170) | 87 (13–151) | 0.09 |
| HIV RNA log copies/ml, median (IQR) | 5.4 (5.0–5.8) | 5.4 (5.0–5.8) | 5.5 (5.2–5.7) | 0.27 |
| ART Regimen d4T+3TC+ nevirapine | 414 (74%) | 294 (76.2%) | 120 (69.4%) | 0.09 |
| AZT+3TC+ efavirenz | 145 (26%) | 92 (23.8%) | 53 (30.6% |
WHO: world Health Organization; BMI: body mass index; Hb: hemoglobin; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; AZT: zidovudine